|
Drug concentration (µM)
|
% of motility on xL3s (average ± SEM)a
|
% of L4 development (average ± SEM)b
|
Adult stage motility score (average ± SEM)a
|
|---|
|
Ivermectin
|
1
|
25.8 ± 11.6c
|
1.4 ± 2.7d
|
0.7 ± 0.5e
|
|
0.1
|
106.0 ± 21.7
|
37.0 ± 9.5d
|
0.6 ± 0.2e
|
|
0.01
|
104.9 ± 23.5
|
66.9 ± 20.7
|
0.7 ± 0.4e
|
|
0.001
|
NT
|
86.7 ± 21.4
|
0.8 ± 0.3e
|
|
0.0001
|
NT
|
NT
|
1.3 ± 0.1e
|
|
Levamisole
|
50
|
0.6 ± 1.6c
|
0.0 ± 0.0d
|
NT
|
|
5
|
72.6 ± 13.4
|
8.9 ± 3.7d
|
0.0 ± 0.0e
|
|
0.5
|
128.1 ± 25.6
|
89.5 ± 3.1
|
0.0 ± 0.0e
|
|
0.005
|
NT
|
NT
|
1.9 ± 0.2
|
|
0.0005
|
NT
|
NT
|
2.8 ± 0.1
|
|
Monepantel
|
2
|
3.5 ± 3.7c
|
4.0 ± 1.1d
|
0.3 ± 0.2e
|
|
0.2
|
9.3 ± 7.1c
|
20.1 ± 18.0d
|
0.7 ± 0.2e
|
|
0.02
|
127.2 ± 26.3
|
85.5 ± 20.5
|
1.0 ± 0.2e
|
|
0.002
|
NT
|
NT
|
2.2 ± 0.1
|
|
Albendazole sulfoxide
|
36
|
37.5 ± 14.5c
|
0.0 ± 0.0d
|
1.0 ± 0.0e
|
|
3.6
|
56.4 ± 13.5c
|
1.9 ± 2.1d
|
1.4 ± 0.3e
|
|
0.36
|
134.8 ± 27.5
|
55.1 ± 16.9d
|
1.3 ± 0.2e
|
|
0.036
|
116.2 ± 20.2
|
74.5 ± 15.4
|
2.3 ± 0.0
|
- Bold numbers indicate that the drug was active at the concentration tested
- aMeasured at 72 h of drug exposure
- bMeasured at 7 days of drug exposure
- NT not tested
- cMotility was significantly different from motility of DMSO control (P < 0.05) (see “Statistical analysis” section for further details)
- dDevelopment was significantly different from development of DMSO control (P < 0.05)) (see “Statistical analysis” section for further details)
- eMotility score of a compound at 72 h time point ≤ 1.5 is considered active[19]
